Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: iPSCs-derived NK cell therapies - Cytovia Therapeutics/Cellectis

Next Previous
Drug Profile

Research programme: iPSCs-derived NK cell therapies - Cytovia Therapeutics/Cellectis

Alternative Names: Induced pluripotent stem cells-derived natural killer cell therapies - Cytovia Therapeutics/Cellectis; Induced pluripotent stem cells-derived NK cell therapies - Cytovia Therapeutics/Cellectis; iPSCs-derived NK cell therapies

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytovia Therapeutics
  • Developer Cellectis; Cytovia Therapeutics
  • Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for research development in Cancer in USA (Parenteral)
  • 17 Mar 2021 Cytovia Therapeutics plans clinical trial for Cancer in Q4 2021 (Parenteral)
  • 16 Feb 2021 Cytovia Therapeutics and Cellectis agree to co-develop iPSCs derived NK cell therapies for Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top